These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 16386986)
1. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Ishizaki E; Takai S; Ueki M; Maeno T; Maruichi M; Sugiyama T; Oku H; Ikeda T; Miyazaki M Am J Ophthalmol; 2006 Jan; 141(1):129-134. PubMed ID: 16386986 [TBL] [Abstract][Full Text] [Related]
2. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666 [TBL] [Abstract][Full Text] [Related]
3. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056 [TBL] [Abstract][Full Text] [Related]
4. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Itakura H; Kishi S; Kotajima N; Murakami M Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550 [TBL] [Abstract][Full Text] [Related]
5. Correlation between ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy. Zheng B; Li T; Chen H; Xu X; Zheng Z Am J Ophthalmol; 2011 Dec; 152(6):1039-43. PubMed ID: 21851923 [TBL] [Abstract][Full Text] [Related]
6. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole patients. Maruichi M; Oku H; Takai S; Muramatsu M; Sugiyama T; Imamura Y; Minami M; Ueki M; Satoh B; Sakaguchi M; Miyazaki M; Ikeda T Curr Eye Res; 2004; 29(4-5):321-5. PubMed ID: 15590479 [TBL] [Abstract][Full Text] [Related]
7. Expression of stromal cell-derived factor-1 in diabetic retinopathy. Chen LY; Zhuo YH; Li YH; Huang XH; Zhang JL; Li SY; Wang XG; Lü L Chin Med J (Engl); 2010 Apr; 123(8):984-8. PubMed ID: 20497701 [TBL] [Abstract][Full Text] [Related]
8. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Wang X; Wang G; Wang Y Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381 [TBL] [Abstract][Full Text] [Related]
9. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Murugeswari P; Shukla D; Rajendran A; Kim R; Namperumalsamy P; Muthukkaruppan V Retina; 2008 Jun; 28(6):817-24. PubMed ID: 18536597 [TBL] [Abstract][Full Text] [Related]
10. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. Funatsu H; Yamashita H; Noma H; Mimura T; Sakata K; Hori S Br J Ophthalmol; 2004 Aug; 88(8):1064-8. PubMed ID: 15258026 [TBL] [Abstract][Full Text] [Related]
11. Effect of retinal laser photocoagulation on the activity of metalloproteinases and the alpha(2)-macroglobulin proteolytic state in the vitreous of eyes with proliferative diabetic retinopathy. Sánchez MC; Luna JD; Barcelona PF; Gramajo AL; Juarez PC; Riera CM; Chiabrando GA Exp Eye Res; 2007 Nov; 85(5):644-50. PubMed ID: 17826767 [TBL] [Abstract][Full Text] [Related]
12. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151 [TBL] [Abstract][Full Text] [Related]
14. [A comparative study of vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy]. Zhou H; Zhang H Zhonghua Yan Ke Za Zhi; 1997 Jul; 33(4):247-50. PubMed ID: 10451953 [TBL] [Abstract][Full Text] [Related]
15. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700 [TBL] [Abstract][Full Text] [Related]
16. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Shimada H; Akaza E; Yuzawa M; Kawashima M Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2953-5. PubMed ID: 19060271 [TBL] [Abstract][Full Text] [Related]
17. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Funatsu H; Yamashita H; Mimura T; Noma H; Nakamura S; Hori S Eye (Lond); 2007 Mar; 21(3):377-82. PubMed ID: 16410812 [TBL] [Abstract][Full Text] [Related]